Marshall Wace
KNSA icon

Marshall Wace’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Marshall Wace’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.7M Buy
305,371
+299,571
+5,165% +$13.3M 0.01% 809
2025
Q4 		$239K Sell
5,800
-55,516
-91% -$2.23M ﹤0.01% 2533
2025
Q3 		$2.38M Sell
61,316
-15,031
-20% -$488K ﹤0.01% 1531
2025
Q2 		$2.11M Buy
+76,347
New +$1.94M ﹤0.01% 1539
2025
Q1 		– Sell
-86,762
Closed -$1.72M – 2880
2024
Q4 		$1.72M Sell
86,762
-3,809
-4% -$86.9K ﹤0.01% 1508
2024
Q3 		$2.26M Buy
+90,571
New +$2.21M ﹤0.01% 1319
2023
Q4 		– Sell
-158,230
Closed -$2.75M – 2405
2023
Q3 		$2.75M Sell
158,230
-167,312
-51% -$2.82M 0.01% 1084
2023
Q2 		$4.58M Sell
325,542
-481,283
-60% -$6.44M 0.01% 1054
2023
Q1 		$8.68M Buy
806,825
+658,886
+445% +$8.68M 0.02% 760
2022
Q4 		$2.22M Buy
+147,939
New +$2.15M 0.01% 1677
2022
Q1 		– Sell
-69,723
Closed -$821K – 3688
2021
Q4 		$821K Buy
+69,723
New +$857K ﹤0.01% 2560
2021
Q1 		– Sell
-78,352
Closed -$1.38M – 2680
2020
Q4 		$1.38M Sell
78,352
-69,951
-47% -$1.23M 0.01% 1080
2020
Q3 		$2.27M Buy
+148,303
New +$2.78M 0.01% 769

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Marshall Wace's KNSA Position: Q1 2026 in Review

Marshall Wace increased its Kiniksa Pharmaceuticals (KNSA) stake by 5,165% in Q1 2026, buying an estimated $13.3M and bringing the position to 305,371 shares worth $14.7M. The position accounts for 0.01% of the portfolio, ranked #809.

Marshall Wace first reported a position in KNSA in Q3 2020 and has held it in 13 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Marshall Wace held 305,371 shares of Kiniksa Pharmaceuticals worth $14.7M as of Q1 2026.
  • Marshall Wace bought 299,571 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $13.3M.
  • Kiniksa Pharmaceuticals made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #809 holding.
  • Marshall Wace first reported a position in Kiniksa Pharmaceuticals in Q3 2020 and has held it in 13 quarters since.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.